| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA828: Ozanimod for treating moderately to severely active ulcerative colitis |
|
Medicine details |
|
| Medicine name | ozanimod (Zeposia®) |
| Formulation | 0.23 mg, 0.46 mg hard capsules |
| Reference number | 2941 |
| Indication | Treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent |
| Company | Receptos Inc |
| BNF chapter | Gastro-intestinal system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/12/2021 |
| NICE guidance | TA828: Ozanimod for treating moderately to severely active ulcerative colitis |
| Commercial arrangement | PAS |